Galera Therapeutics, Inc. (GRTX)
- Previous Close
0.1771 - Open
0.1768 - Bid 0.1732 x 100
- Ask 0.1779 x 200
- Day's Range
0.1575 - 0.1775 - 52 Week Range
0.0850 - 3.5900 - Volume
1,030,159 - Avg. Volume
2,064,547 - Market Cap (intraday)
9.578M - Beta (5Y Monthly) 2.03
- PE Ratio (TTM)
-- - EPS (TTM)
-1.3300 - Earnings Date May 13, 2024 - May 20, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.50
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
www.galeratx.comRecent News: GRTX
Performance Overview: GRTX
Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GRTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GRTX
Valuation Measures
Market Cap
9.58M
Enterprise Value
-7.43M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-83.63%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-59.08M
Diluted EPS (ttm)
-1.3300
Balance Sheet and Cash Flow
Total Cash (mrq)
18.26M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-35.66M
Research Analysis: GRTX
Company Insights: GRTX
GRTX does not have Company Insights